首页> 外文OA文献 >Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment

【2h】

Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment

机译：新型BEZ235，pI3K / mTOR抑制剂和依维莫司组合的临床药代动力学，mTOR抑制剂：I期临床研究和非临床机械评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Moorthy Ganesh;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种 English
中图分类

相似文献

外文文献
中文文献
专利

1. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. [J] . Awada A, Cardoso F, Fontaine C, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2008,第1期

机译：晚期乳腺癌患者中口服mTOR抑制剂RAD001（依维莫司）与来曲唑合用：药物动力学第一期研究的结果。
2. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer [J] . Rodon Jordi, Perez-Fidalgo Alejandro, Krop Ian E., Cancer chemotherapy and pharmacology. . 2018,第2期

机译：在患有先进乳腺癌的患者的患者中，BEZ235，双PI3K / MTOR抑制剂的BEZ235，双PI3K / MTOR抑制剂的升级和膨胀研究
3. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer [J] . Xiao X. Wei, Andrew C. Hsieh, Won Kim, The oncologist . 2017,第5期

机译：醋酸阿比特龙联合PI3K / mTOR双重抑制剂BEZ235在转移性去势抵抗性前列腺癌中的I期研究
4. Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells. [C] . Fateye, Babasola, Chen Bin Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XX . 2011

机译：内皮细胞和肿瘤细胞中PI3K / Akt / mTOR抑制剂和PDT的组合。
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies [O] . Trisha M. Wise-Draper, Ganesh Moorthy, Mohamad A. Salkeni, -1

机译：晚期实体恶性肿瘤患者双重PI3K / mTOR抑制剂Dactolisib（BEZ235）联合依维莫司的Ib期研究
7. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies [O] . 2017

机译：晚期实体恶性肿瘤患者双重PI3K / mTOR抑制剂Dactolisib（BEZ235）联合依维莫司的Ib期研究

Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment

著录项

引文网络

相似文献

相关主题

期刊订阅